{
  "id": "61f5fe43882a024a1000001c",
  "type": "summary",
  "question": "What is GLS-5700?",
  "ideal_answer": "GLS-5700 is a synthetic, consensus DNA vaccine encoding the ZIKV premembrane and envelope proteins that was tested for Zika virus disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34525286",
    "http://www.ncbi.nlm.nih.gov/pubmed/30053014",
    "http://www.ncbi.nlm.nih.gov/pubmed/28976850"
  ],
  "snippets": [
    {
      "text": "ETHODS: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34525286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods: Male IFNAR-/- mice, knockout for type I interferon receptor, were immunized with GLS-5700, a deoxyribonucleic acid-based vaccine, before a subcutaneous ZIKV challenge with 6 \u00d7 105 plaque-forming units at 13 weeks of age.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "thods: Male IFNAR-/- mice, knockout for type I interferon receptor, were immunized with GLS-5700, a deoxyribonucleic acid-based vaccine, before a subcutaneous ZIKV challenge with 6 \u00d7 105 plaque-forming units at 13 weeks of age. O",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THODS: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34525286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ods In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. The par",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28976850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " infection.METHODS: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 2",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34525286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cient mice.Methods: Male IFNAR-/- mice, knockout for type I interferon receptor, were immunized with GLS-5700, a deoxyribonucleic acid-based vaccine, before a subcutaneous ZIKV challenge with 6 \u00d7 105 plaque-forming units",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background: Zika virus (ZIKV) infection has been associated with prolonged viral excretion in human semen and causes testicular atrophy and infertility in 10-week-old immunodeficient mice.Methods: Male IFNAR-/- mice, knockout for type I interferon receptor, were immunized with GLS-5700, a deoxyribonucleic acid-based vaccine, before a subcutaneous ZIKV challenge with 6 \u00d7 105 plaque-forming unit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30053014",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " described. There are no approved vaccines against ZIKV infection.METHODS: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34525286",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}